Trusted local news leader for Prescott area communities since 1882
Thu, June 17

FDA approves much-debated Alzheimer's drug panned by experts

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)

To view this content you must be logged in as a subscriber.
Already have a digital account? Log in here
4 WEEKS
$6

UNLIMITED

DIGITAL ACCESS

4 WEEKS

1 YEAR
$78

UNLIMITED

DIGITAL ACCESS

FOR 12 MONTHS

DAY PASS
$2.99

UNLIMITED

DIGITAL ACCESS

FOR 24 HOURS

Plans include full website access, e-Edition and exclusive online extras.
Print and Digital combo plans also available.
ALREADY A PRINT SUBSCRIBER?
dcourier subscribe logo
Donate Report a Typo Contact
Most Read
Event Calendar
Event Calendar link
Submit Event